Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financi... (

Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results

Date:3/13/2008

- Pipeline Update Conference Call and Webcast on March 14 at 8:00 a.m. PDT

SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today reported financial results for the three months and year ended December 31, 2007.

"Our achievements in 2007 have advanced our partnered programs, while building a strong foundation for our proprietary programs. We are pursuing a number of exciting opportunities to build shareholder value and will be presenting clinical and pre-clinical data on a number of these programs throughout 2008," said Jonathan Lim, MD, Halozyme's President and CEO. "By continuing to leverage the franchises of our partners and expanding upon our broad and deep scientific expertise in the extracellular matrix, we plan to develop therapeutic and aesthetic drugs in oncology, dermatology, and metabolism."

Upcoming Scientific Data Presentations

-- American Academy of Allergy Asthma & Immunology (AAAAI) 2008 Annual

Meeting -- March 14-18th -- presentation of GAMMAGARD / Enhanze

Technology Phase I/IIa data

-- American Association of Cancer Research (AACR) Annual Meeting

2008 -- April 12-16th -- presentation of subcutaneous bisphosphonates /

rHuPH20 pre-clinical data

-- American Association of Cancer Research (AACR) Annual Meeting 2008 --

April 12-16th -- presentation of systemic PEG rHuPH20 in solid tumor

models pre-clinical data

Fourth Quarter 2007 Highlights

-- The Original Article publication of the INFUSE-LR clinical trial

results in the Jo
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway

Post Your Comments:

Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financi...( - Pipeline Update Conference Call an...)